2022
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, RheumatoidCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedRheumatologySurveys and QuestionnairesConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regressionManagement of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
Jin S, Jiang N, Huo Y, Duan X, Fang Y, Zhao C, Li H, Yang M, Huang Z, Yang P, Zhang H, Zhan F, Wang Y, Wang Y, Wu C, Wang Q, Hsieh E, Li M, Tian X, Zhao Y, Zeng X. Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations. Annals Of The Rheumatic Diseases 2022, 81: 1052-1054. PMID: 35168947, DOI: 10.1136/annrheumdis-2021-221841.Peer-Reviewed Original Research
2021
Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment
Hanberg JS, Hsieh E, Akgün KM, Weinstein E, Fraenkel L, Justice AC, Team T. Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment. Arthritis & Rheumatology 2021, 73: 2189-2199. PMID: 34042306, DOI: 10.1002/art.41802.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntirheumatic AgentsArthritis, RheumatoidComorbidityFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedPrevalenceConceptsDisease-modifying antirheumatic drugsIncident rheumatoid arthritisDiagnosis of RARA patientsRheumatoid arthritisRheumatoid factorUninfected individualsRheumatology/European AllianceHigh titersVeterans Aging Cohort StudyRA-specific autoantibodiesRheumatology 2010 criteriaTenth Revision codesAging Cohort StudyIncidence rate ratiosHigh autoantibody titersICD-10 codesDMARD useUninfected veteransAntirheumatic drugsAutoantibody titersCohort studyImmunosuppressed populationHIV infectionMedical chartsBone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT
Jin S, Li M, Wang Q, Zeng X, Xia W, Yu W, Guan W, Hsieh E. Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT. Arthritis Research & Therapy 2021, 23: 127. PMID: 33894786, PMCID: PMC8067377, DOI: 10.1186/s13075-021-02503-0.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonArthritis, RheumatoidBone DensityChinaCross-Sectional StudiesFemaleHumansRadiusTibiaConceptsBone mineral densityRheumatoid arthritisRisk of fractureCross-sectional studyMineral densityFragility fracturesDistal radiusHealthy controlsBone microarchitectureBone strengthHigh-resolution peripheral quantitative computed tomographySex-matched healthy controlsPeripheral quantitative computed tomographyDual-energy X-ray absorptiometryVolumetric bone mineral densityFemale reproductive factorsRA-related characteristicsThoracolumbar X-rayTraditional risk factorsQuantitative computed tomographyX-ray absorptiometryCortical bone thicknessThin cortical boneGroup of ageChinese Registry
2020
Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target
Xiang Y, Wang Q, Li H, Duan X, Fang Y, Yang P, Li Q, Wu R, Huo Y, Shi X, Wu Z, Wang Y, Jiang N, Hsieh E, Li M, Tian X, Zeng X, co‐authors C. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target. International Journal Of Rheumatic Diseases 2020, 23: 1719-1727. PMID: 33034424, DOI: 10.1111/1756-185x.13996.Peer-Reviewed Original ResearchConceptsBiologic disease-modifying anti-rheumatic drugsDisease activityTreatment responseChinese RegistryRheumatoid arthritisDisease-modifying anti-rheumatic drugsBaseline Disease Activity ScoreConventional DMARD therapyLower baseline DAS28Baseline disease activityDisease Activity ScoreAnti-rheumatic drugsBaseline DAS28DMARD therapyLDA ratesPrednisolone usageSynthetic DMARDsEarly RADisease durationActivity scoreTreatment strategiesTreatment targetsYounger agePatientsBaseline